1 - 10 toradh á dtaispeáint as 10 toradh san iomlán ar an gcuardach 'Elisabeth I. Heath (15024674)', am iarratais: 0.01s Beachtaigh na torthaí
  1. 1
    Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer

    Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer de réir Ulka N. Vaishampayan (15051039)

    Foilsithe / Cruthaithe 2025
    Rannpháirtithe:
    Cuir le mo chuid Ceanán
    Sábháilte in:
  2. 2
    Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer

    Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer de réir Ulka N. Vaishampayan (15051039)

    Foilsithe / Cruthaithe 2025
    Rannpháirtithe:
    Cuir le mo chuid Ceanán
    Sábháilte in:
  3. 3
    Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer

    Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer de réir Ulka N. Vaishampayan (15051039)

    Foilsithe / Cruthaithe 2025
    Rannpháirtithe:
    Cuir le mo chuid Ceanán
    Sábháilte in:
  4. 4
    Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer

    Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer de réir Ulka N. Vaishampayan (15051039)

    Foilsithe / Cruthaithe 2025
    Rannpháirtithe:
    Cuir le mo chuid Ceanán
    Sábháilte in:
  5. 5
    Supplementary Table 2 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes

    Supplementary Table 2 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes de réir Justin Hwang (15925675)

    Foilsithe / Cruthaithe 2025
    Rannpháirtithe:
    Cuir le mo chuid Ceanán
    Sábháilte in:
  6. 6
    Supplementary Table 1 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes

    Supplementary Table 1 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes de réir Justin Hwang (15925675)

    Foilsithe / Cruthaithe 2025
    Rannpháirtithe:
    Cuir le mo chuid Ceanán
    Sábháilte in:
  7. 7
    Supplementary Figure 3 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes

    Supplementary Figure 3 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes de réir Justin Hwang (15925675)

    Foilsithe / Cruthaithe 2025
    Rannpháirtithe:
    Cuir le mo chuid Ceanán
    Sábháilte in:
  8. 8
    Supplementary Table 3 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes

    Supplementary Table 3 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes de réir Justin Hwang (15925675)

    Foilsithe / Cruthaithe 2025
    Rannpháirtithe:
    Cuir le mo chuid Ceanán
    Sábháilte in:
  9. 9
    Supplementary Figure 1 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes

    Supplementary Figure 1 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes de réir Justin Hwang (15925675)

    Foilsithe / Cruthaithe 2025
    Rannpháirtithe:
    Cuir le mo chuid Ceanán
    Sábháilte in:
  10. 10
    Supplementary Figure 2 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes

    Supplementary Figure 2 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes de réir Justin Hwang (15925675)

    Foilsithe / Cruthaithe 2025
    Rannpháirtithe:
    Cuir le mo chuid Ceanán
    Sábháilte in:

Uirlisí cuardaigh: